Surviving cancer is often not a patient’s most challenging battle

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

With advances in treatment and screening for earlier detection, oncologists have improved cancer survival rates dramatically. That is excellent news, but the surging number of survivors means it is increasingly important for providers to focus more diligently on what patients need to thrive after treatment.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Boris C. Pasche, MD, PhD
President and CEO, Karmanos Cancer Institute, Chair, Department of Oncology, Wayne State University School of Medicine
Table of Contents

YOU MAY BE INTERESTED IN

In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 
Boris C. Pasche, MD, PhD
President and CEO, Karmanos Cancer Institute, Chair, Department of Oncology, Wayne State University School of Medicine

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login